SCHEMBL23329282

SCHEMBL23329282

O=C(O)c1[nH]nnc1-c1ccc(F)c(Cl)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMO O15229 3/20 0.47
RPA1 P27694 1/20 0.46
ADORA2A P29274 1/20 0.43
ADORA1 P30542 1/20 0.43
CASP1 P29466 1/20 0.43
ERCC1 P07992 1/20 0.40
ERCC4 Q92889 1/20 0.40
HAO1 Q9UJM8 3/20 0.39
MARS1 P56192 1/20 0.39
ALPL P05186 2/20 0.39
CA12 O43570 1/20 0.39
MDM2 Q00987 1/20 0.39
NR3C1 P04150 1/20 0.39
PGR P06401 1/20 0.39
NR3C2 P08235 1/20 0.39
AR P10275 1/20 0.39
NISCH Q9Y2I1 1/20 0.38
MAP2K4 P45985 1/20 0.38
XDH P47989 1/20 0.37
PIK3CA P42336 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23294649 0.94 KMO (0.45) KMORPA1ADORA2AADORA1CASP1
SCHEMBL22608235 0.87 KMO (0.48) KMOHAO1XDH
SCHEMBL23294391 0.84 KMO (0.38) KMOHAO1ALPLXDH
SCHEMBL29852150 0.83 KMO (0.45) KMOHAO1ALPLMAP2K4XDH
SCHEMBL22816678 0.83 MARS1 (0.52) HAO1MARS1ALPLCA12MAP2K4
SCHEMBL29852165 0.83 MARS1 (0.52) HAO1MARS1ALPLCA12MAP2K4
SCHEMBL23294635 0.83 KMO (0.45) KMOHAO1ALPLMAP2K4XDH
SCHEMBL23294603 0.82 HAO1 (0.49) KMOHAO1MARS1ALPLCA12
SCHEMBL23294638 0.81 KMO (0.48) KMOHAO1MAP2K4XDH
SCHEMBL23294301 0.81 MARS1 (0.46) HAO1MARS1ALPLMAP2K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11806335-B2 Heterocyclic carboxylate compounds as glycolate oxidase inhibitors Lilac Therapeutics, Inc. (US) 2023-11-07 US disclosed
US-11806335-B2 Heterocyclic carboxylate compounds as glycolate oxidase inhibitors Lilac Therapeutics, Inc. (US) 2023-11-07 US disclosed
US-20210128532-A1 HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS Lilac Therapeutics, Inc. 2021-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11806335-B2 Heterocyclic carboxylate compounds as glycolate oxidase inhibitors UGDH, PGD, PNPO KMO 528/4885RPA1 3390/4885ADORA2A 4360/4885
US-20210128532-A1 HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS UGDH, PGD, PNPO KMO 528/4885RPA1 3390/4885ADORA2A 4360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.